{"componentChunkName":"component---src-pages-references-js","path":"/references/","result":{"data":{"allNodeReferences":{"nodes":[{"field_headertext":"References","field_references":[{"processed":"<p>Atkins C, Bonagura J, Ettinger S, <em>et al</em>. Guidelines for the Diagnosis and Treatment of Canine Chronic Valvular Heart Disease.<em> J Vet Intern Med.</em> 2009;23(6):1142-1150.</p>"},{"processed":"<p>Fuentes VL, ed. <em>BSAVA Manual of Canine and Feline Cardiorespiratory Medicine</em>. 2. ed. Quedgeley: 2. BSAVA; 2010.</p>"},{"processed":"<p>Ljungvall I, Rishniw M, Porciello F, <em>et al</em>. Murmur intensity in small-breed dogs with myxomatous mitral valve disease reflects disease severity. <em>J Small Anim Pract</em>. 2014;55(11):545-550.</p>"},{"processed":"<p>Boswood A, Häggström J, Gordon SG, et al. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial. <em>J Vet Intern </em>Med. 2016;30(6):1765-1779.</p>"},{"processed":"<p>Cornell C, Kittleson M, Della Torre P, <em>et al.</em> Allometric scaling of M-mode cardiac measurements in normal adult dogs. <em>J Vet Intern Med.</em> 2004;18(3):311-321. </p>"},{"processed":"<p>Keene, BW, Atkins, CE, Bonagura, JD, <em>et al.</em> ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. <em>J Vet Intern Med.</em> 2019; 33: 1127– 1140.</p>"}],"field_prescribinginformation":{"processed":"<p>Vetmedin® Chew 1.25 mg, 5 mg and 10 mg chewable tablets for dogs. Active substance: Pimobendan. Uses: For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regurgitation). (See also section 4.9 of the SPC). For the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter) in Doberman Pinschers following echocardiographic diagnosis of cardiac disease (see sections 4.4 and 4.5 of the SPC). For the treatment of dogs with myxomatous mitral valve disease (MMVD) in the preclinical stage (asymptomatic with a systolic mitral murmur and evidence of increased heart size) to delay the onset of clinical symptoms of heart failure (see sections 4.4 and 4.5 of the SPC). UK: POM-V IE: POM. For information about side effects, precautions, warnings and contraindications please refer to the product packaging and package leaflet. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: <a href=\"tel:01344746959\">01344 746959</a> (sales) or <a href=\"tel:01344746957\">01344 746957</a> (technical), IE Tel: <a href=\"tel:012913985\">01 291 3985</a> (all queries).</p>\n\n<p>Email: <a href=\"mailto:vetenquiries@boehringer-ingelheim.com\">vetenquiries@boehringer-ingelheim.com</a>. Vetmedin® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2020 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: April 2020. UI-CAN-0047-2020. Use Medicines Responsibly.</p>"},"path":{"alias":"/references"}}]},"allNodeGenericpagefurniture":{"nodes":[{"field_bodytext":{"processed":"<p>Vetmedin® Chew 1.25 mg, 5 mg and 10 mg chewable tablets for dogs. Active substance: Pimobendan. Uses: For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regurgitation). (See also section 4.9 of the SPC). For the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter) in Doberman Pinschers following echocardiographic diagnosis of cardiac disease (see sections 4.4 and 4.5 of the SPC). For the treatment of dogs with myxomatous mitral valve disease (MMVD) in the preclinical stage (asymptomatic with a systolic mitral murmur and evidence of increased heart size) to delay the onset of clinical symptoms of heart failure (see sections 4.4 and 4.5 of the SPC). UK: POM-V IE: POM. For information about side effects, precautions, warnings and contraindications please refer to the product packaging and package leaflet. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: <a href=\"tel:01344746959\">01344 746959</a> (sales) or <a href=\"tel:01344746957\">01344 746957</a> (technical), IE Tel: <a href=\"tel:012913985\">01 291 3985</a> (all queries).</p>\n\n<p>Email: <a href=\"mailto:vetenquiries@boehringer-ingelheim.com\">vetenquiries@boehringer-ingelheim.com</a>. Vetmedin® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2020 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: April 2020. UI-CAN-0047-2020. Use Medicines Responsibly.</p>"}}]}},"pageContext":{}}}